NCT02860819View on ClinicalTrials.gov

Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 1, 2016

Primary Completion Date

November 30, 2020

Study Completion Date

February 15, 2021

Conditions
Testicular Cancer
Interventions
DRUG

Veliparib

Veliparib 250mg BID, continuously

DRUG

Gemcitabine

Gemcitabine 800mg/m2, day 1 and 8

DRUG

Carboplatin

Carboplatin AUC = 4, day 1

Trial Locations (1)

83310

National Cancer Institute, Bratislava

All Listed Sponsors
lead

National Cancer Institute, Slovakia

OTHER_GOV

NCT02860819 - Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer | Biotech Hunter | Biotech Hunter